Chem-/Biotech

Reconstruction of diseased urinary organs

UROTEC GmbH

Urotech GmbH was a biotech company that uses patient’s own cells to produce tissue substitutes for the reconstruction of diseased urinary organs.

TGFS became a shareholder in Urotech GmbH in 2009. Another investor was High-Tech Gründerfonds (HTGF). In 2010, the joint exit took place as part of the sale to APOGEPHA Arzneimittel GmbH.